Home > Boards > US Listed > Cannabis >

Rafarma Pharmaceuticals Inc. (RAFA)

Add RAFA Price Alert      Hide Sticky   Hide Intro
Moderator: PEACHMAN, IB_, Investorr, madtrader2132, ScottRVA1
Search This Board: 
Last Post: 5/13/2021 7:09:27 PM - Followers: 100 - Board type: Free - Posts Today: 0

Official Website:

Current Share Structure:

Leadership Page:

Rafarma is actively involved in the process of establishing contractual partnerships with approximately 200 companies in various countries, to be finalized by the summer of 2022. 

>These include the USA, the EU and the ASEAN countries, China, Japan, Singapore, South Africa and Russia. Contractual partnerships have already been finalized with several companies in China, Uzbekistan, Czech Republic, Singapore, Malaysia and Russia.

Current R & D Projects:

Location: Haifa, Israel, 2021, Joint Venture with the Matam Technopark in Haifa, Israel
-Exosome research for pharmaceutical production and use, as well as joint research toward an artificially-created, modified bacterium to form a therapeutic platform for new drug designs.

Location: Uzbekistan, 2021, Joint Venture with Health Department of Uzbekistan
-Projected costs are currently at $82,000,000
-Construction started in Early 2021.
See the construction here:

Location: Moscow, 2021, Self-funded
Construction of site for contact production of adenovirus vector

Location: Batan - Indonesia, 2021-2023, Self-funded + bond loan
Construction of a plant and laboratories in Indonesia

Location: Krasnoyarsk-Russia, Czech Republic, 2021-25, Self-funded
Construction of production sites for sterile preparations

Location: Yver Region - Russia, 2021, Self-funded + bank loans
Construction of production sites for non-sterile drugs

Location: Dubna - Moscow Region, 2020-21, Self-funded
Reconstruction of an enterprise for radioopharmaceuticals

Location: Krasnoyarsk-Russia, 2020-21, Self-funded
Reconstruction of the R & D lab

Location: Istanbul-Turkey, 2021-25
Istanbul nuclear medicine center project

Location: Pereslavi-Russia, 2021-23
Nuclear medicine center near Moscow

Location: New York - USA, 2021-22
Construction of a laboratory on artificial immunity technologies in the suburbs of New York

Location: Kumertau-Bashkiria, Pereslavi-Yaroslavl region 2021-24
Reconstruction/construction of biotechnological production centers in the Czech Republic, Yaroslavi region, Bashkiria

Merged has closed!:

Reverse Merger of Biocogency into Rafarma Pharmaceuticals Creates Substantial Unrealized Shareholder Value:

Biocogency with $73 million 2019 sales recently acquired majority control and merged all operations into Rafarma Pharmaceuticals

There was no dilution to Rafarma shareholders and all operations and assets of both companies will be combined and reported under the ticker RAFA

The merger increased Rafarma Pharmaceuticals 2019 revenues from $11.4 million to $84 million

Elite accounting firm, L. J. Soldinger is retained to perform audited financials

Wealthy international industrialist, Ilya Shpurov is now Chairman of the Board of Rafarma Pharmaceuticals

  • With 2019 combined sales of $84 million, current market cap of $131 million, extraordinary strong growth, and share price of $1.69, market comps point to share price valuation several multiples higher than current price

Many OTC stocks are easily overlooked because they don't get the coverage of peers traded on national exchanges and consequently very few investors have the opportunity to know about them. A perfect example is the recent closing of a reverse merger increasing sales by over 700% and adding sizable international operations of private Biocogency into Rafarma Pharmaceuticals (OTC: RAFA) where the RAFA share price has not yet reflected the new added value.


On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price is expected to begin climbing to more fair and reasonable market valuations that could exceed expectations.


About Rafarma Pharmaceuticals

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.

About Biocogency

Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.

The Company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.

A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.

Safe and effective generic medicines of PJSC "Kraspharma", which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.

Today PJSC "Kraspharma" is the Eastern Europe and Russia undisputed leader in the production of:

  • Antibiotics;
    tuberculosis drugs in injectable forms;
    Blood substitutes;
    infusion solutions;
    Preparations of other pharmacological groups.

Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the Government of the Russian Federation.

The products of PJSC "Kraspharma" are sold in Russia, Eastern Europe, Central Asia and in the countries of the Asia-Pacific region.

What Biocogency Adds to Rafarma


This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.


The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia's largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of a variety of products including packaging goods, materials for microelectronics and photo materials, are both steeped in corporate history going back half a century or more in Russia.


Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.


What's in it for RAFA? An Immediate Spike in Revenue and Profits


The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.


Those results are going to get an immediate shot of adrenaline.


During fiscal 2019, the Biocogency group reported unaudited consolidated earnings of $73 million and gross profits of $17 million. As a course of becoming fully reporting and planning to uplist, the financial results are being audited and adjusted to meet GAAP standards.


Using the results from 2019, it is easy to extrapolate pro forma revenue of $84.4 million and gross profit of $20.3 million for the combined company. It is those type of financials that will underpin a move to the Nasdaq or NYSE.


More on how the price to sales ratio stacks up to industry comps are discussed here. Several Pharmaceutical market comps point to Rafarma share prices that are many multiples higher than the current price of $1.69.


When it comes to value, it certainly bears mentioning the investments that Biocogency has put into its pipeline and platforms since 2012, which management pegs at more than $120.0 million. Much of this investment has been directed by Shpurov since he bought the Kraspharma during the outbreak of the global financial collapse in 2008 for the purpose of restoring and expanding production volumes post-recession while establishing a high-tech GMP pharmaceutical manufacturer in Krasnoyarsk.


That was accomplished. Today, Kraspharma is a leading producer of wide swath of generic drugs and pharma products spanning antibiotics, blood substitutes, infusion solutions, tuberculosis and preparations for other pharmacological groups. Sales channels extend throughout Russia, Eastern Europe and the Asia-Pacific region.


Widening the Footprint


The plan is for vertical growth by expanding the existing channels while leveraging RAFA relationships for horizontal growth through entering the lucrative North American markets.


In fairness, Russia alone can be a company maker. A huge net importer of medicine, the Russian government is pushing for national security in the supply chain as outlined in the Pharma 2030 Strategy. With that in mind, Statista forecasts the Russian pharmaceutical industry will grow 147% between 2017 and 2030.


During Q1, the Russian pharma market surged 125% year-over-year to about 320 billion Russian rubles (US$4.2 billion). Generic drugs typically dominate the prescription market, accounting for 64.5% of the category in 2017, meaning Kraspharma is in a strong position.


Given the sheer volume of people, Asia is another tremendous market. The Rx market in China alone is forecast to reach $160 billion by 2022, highlighting the market opportunity. With respect to the Asian drug development market, ResearchAndMarkets estimates 6.54% compound annual growth to reach $62.46 billion by 2026.


Still, the U.S. is the Holy Grail as the biggest pharmaceutical market in the world, weighing in at a whopping $484.4 billion in 2018.



With the reverse merger now closed, the newly created Rafarma Pharmaceuticals that now boasts fast-growing operations well in excess of $100 million for 2019 is decidedly undervalued when compared to industry valuations for similar companies. Management plans for uplisting and higher investor awareness programs are soon in the future which will help bring the Rafarma opportunity to the forefront resulting in substantially higher prices and trading volume.

The current price has not yet appreciated to reflect the newly increased sales and valuations and therefore presents an opportunity to astute investors who act now before the story becomes more commonly known.


The asia hemp market will be huge!

This analyst explains the company well:
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RAFA News: Rafarma Pharmaceuticals plans for aggressive global growth in 2021-22 03/04/2021 11:15:20 AM
RAFA News: Reverse Merger of Biocogency into Rafarma Pharmaceuticals Creates Substantial Unrealized Shareholder Value 11/17/2020 10:56:59 AM
#5588  Sticky Note Great news! RAFA will be a worldwide conglomerate. Investorr 04/30/21 10:37:11 AM
#5190  Sticky Note more birdman- honest report from the court snakess 10/26/20 10:09:12 PM
#5598   GC, We could get Q1 2021 financials Investorr 05/13/21 07:09:27 PM
#5597   Good luck Go RAFA BProfit 05/13/21 04:49:44 PM
#5596   Its going Golden_Cross 05/13/21 04:44:37 PM
#5595   How is your DD going? BProfit 05/13/21 04:05:01 PM
#5594   Thank you... Golden_Cross 05/11/21 11:27:08 AM
#5593   Just know that there has been 0 dilution Investorr 05/11/21 11:04:42 AM
#5592   Going to be doing more DD on RAFA Golden_Cross 05/11/21 05:05:42 AM
#5591   Great. Thanks GC! Investorr 05/11/21 03:50:43 AM
#5590   RAFA Now Pink Current Golden_Cross 05/11/21 03:43:39 AM
#5589   Nice news! Proton Therapy Centers will be big! Investorr 05/07/21 09:44:47 AM
#5588   Great news! RAFA will be a worldwide conglomerate. Investorr 04/30/21 10:37:11 AM
#5587   RAFA still expanding http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn speedo94947 04/30/21 09:43:56 AM
#5585  Restored Covered my 32,000 RAFA short position today !!!!!!!!!!!!!!!!!! IB_ 04/23/21 08:28:56 PM
#5584   Findings should verify the recently released financials. Investorr 04/21/21 12:50:09 PM
#5583   Anyone have any updates or thoughts on the ScottRVA1 04/21/21 10:03:19 AM
#5582  Restored DD for RAFA is done by the bird. reverse_long 04/18/21 12:32:25 AM
#5581   Smart move- revs will see a massive bump surfgreen 04/16/21 12:05:55 PM
#5580   Volume light, pps down... I’m picking up 1/4 ScottRVA1 04/16/21 12:01:28 PM
#5579   Wow! Great earnings. Things are heating up with Investorr 04/15/21 07:05:29 PM
#5578   $RAFA #Rafarma Pharmaceuticals 2020 Financial Highlights > $74.7 Million Reven madtrader2132 04/15/21 06:56:25 PM
#5577   Annual report 75Mill Rev and .169 Eps https://backend.otcmarkets.com/otcapi/comp speedo94947 04/15/21 06:42:23 PM
#5575   RAFA slowly moving back up and could move PEACHMAN 04/14/21 04:21:35 PM
#5572   In my opinion your making a mistake. i PEACHMAN 04/14/21 10:35:14 AM
#5571   Great News Today by Rafa owned Bebig. Investorr 04/14/21 10:18:48 AM
#5570  Restored Too many, by the looks of things this IB_ 04/14/21 09:38:25 AM
#5569  Restored How many shares ? ricksterva 04/13/21 05:41:57 PM
#5568   Went short RAFA at $2.40 .................. Wish me IB_ 04/13/21 03:25:54 PM
#5567   I think they have until 4/14 or 4/15. Investorr 04/09/21 11:35:03 AM
#5566   Any insights on why 4Q hasn’t come out ScottRVA1 04/09/21 10:47:11 AM
#5565   Additional RAFA due diligence PEACHMAN 04/08/21 09:11:09 AM
#5564   And the Jets would of won a super knick 04/06/21 05:28:39 PM
#5563   Earnings ‘due’ today but I’m betting they could ScottRVA1 04/06/21 01:48:55 PM
#5562   No crystal ball here I thought Gonzaga would PEACHMAN 04/06/21 08:53:09 AM
#5561   Any timeframe for uplifting? TIA knick 04/06/21 08:49:16 AM
#5560   Some New RAFA videos PEACHMAN 04/05/21 04:06:46 PM
#5559   Earnings are due out tomorrow! Audit hopefully within ScottRVA1 04/05/21 03:35:26 PM
#5558   New high today for RAFA 3.07 PEACHMAN 03/29/21 04:49:14 PM
#5557   https://youtu.be/RfMChY9V7-I madtrader2132 03/27/21 08:48:50 AM
#5553   https://www.youtube.com/channel/UC7jKQcKLBt7uiikzDJC1Aag/videos madtrader2132 03/26/21 12:44:44 PM
#5549   RAFA nearing $3 break here MG123 03/26/21 10:50:05 AM
#5548   $RAFA Kraspharma Plant Increased production of Antibiotics and PEACHMAN 03/26/21 10:47:47 AM
#5538   Love the RAFA video today! With Investorr 03/24/21 05:46:49 PM
#5535   Let's play nice at RAFA...Ignore and know what PEACHMAN 03/22/21 04:49:43 PM
#5533   Is RAFA the other $300.00 stock !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! IB_ 03/22/21 11:54:48 AM
#5532   I noticed that the company has updated website MG123 03/21/21 04:31:30 AM
#5531   Very good company here, pps will be much MG123 03/21/21 04:30:19 AM
#5530   Can't wait. Bought stock in may 2019. It BProfit 03/19/21 05:51:07 PM
#5529   $RAFA$ Volume jump precedes price. Multi million volume surfgreen 03/19/21 03:39:25 PM
#5528   Lookin good today BProfit 03/19/21 03:15:03 PM
#5527   RAFA only follows 70 accounts on Twitter and 71nLong 03/18/21 08:16:18 AM
Consent Preferences